case_images: PMC4860976_01
case_images: Wound dehiscence and scleral exposure in the first patient, 10 days after Ahmed Glaucoma Valve implantation with adjunctive subconjunctival bevacizumab.
case_images: JOVR-11-112-g001.jpg
case_images: PMC4860976_01_JOVR-11-112-g001.jpg
case_images: F1
case_images: On day 3 after admission, anterior migration of the tube and complete wound dehiscence was observed [Figures 1 and 2].
case_images: Tube migration after Ahmed Glaucoma Valve implantation with adjunctive subconjunctival bevacizumab in the first patient.
case_images: JOVR-11-112-g002.jpg
case_images: PMC4860976_01_JOVR-11-112-g002.jpg
case_images: F2
case_images: On day 3 after admission, anterior migration of the tube and complete wound dehiscence was observed [Figures 1 and 2].
case_images: PMC4860976_02
case_images: Plate exposure in the second patient 5 months after Ahmed Glaucoma Valve implantation with adjunctive subconjunctival bevacizumab.
case_images: JOVR-11-112-g003.jpg
case_images: PMC4860976_02_JOVR-11-112-g003.jpg
case_images: F3
case_images: During repeat surgery, migration of the AGV and melting of the scleral patch graft were observed [Figure 3].